Xcout IntelAMBERSTONE BIOSCIENCES, INC.
Amberstone Biosciences, Inc. is an early-stage biotechnology firm that pioneers next-generation tumor-activated immunotherapeutics to discover transformative, safe, and effective treatments.
Subscribe to see AMBERSTONE BIOSCIENCES, INC.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AMBERSTONE BIOSCIENCES, INC. at a glance
AMBERSTONE BIOSCIENCES, INC. is a biotechnology company headquartered in United States. Its most recent funding round, Series A, raised $12M in July 2026. Xcout tracks 2 named people at AMBERSTONE BIOSCIENCES, INC., including George Wu (founder).
AMBERSTONE BIOSCIENCES, INC. leadership
- George Wufounder
- Weian Zhaofounder
AMBERSTONE BIOSCIENCES, INC. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $12M | 8 named | |
| — | $150M | 5 named | |
| SEC Form D filing | $6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
AMBERSTONE BIOSCIENCES, INC. competitors
A few of AMBERSTONE BIOSCIENCES, INC.'s closest competitors — see the full list of competitors and alternatives →
ARMO BioSciences is a late-stage immuno-oncology company that develops a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
Gritstone bio, Inc. is a clinical-stage biotechnology company headquartered in Emeryville, California. The firm engages in developing next-generation cancer immunotherapies and vaccines to fight various forms of cancer and infectious diseases.
Attivare Therapeutics, Inc. is a privately held biotechnology research company focused on developing innovative immuno-therapeutics designed to effectively treat tumors with low immunogenicity.
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Daylight Biotherapeutics is a biotechnology holding company operating in stealth mode in the United States. The company is developing a novel T cell engaging technology designed to decouple tumor killing from systemic immune activation.
Lytix Biopharma is a clinical-stage biotechnology company developing oncolytic molecule therapies to treat superficial and deep-seated tumors. The company focuses on the neoadjuvant setting, providing first-in-class immunotherapies designed to destroy cancer cell membranes and stimulate a broad immune response.
Get AMBERSTONE BIOSCIENCES, INC.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about AMBERSTONE BIOSCIENCES, INC.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on AMBERSTONE BIOSCIENCES, INC. in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access